Ipca Laboratories has announced a partnership with BioSimilar Sciences PR LLC (BSS) in the United States to develop a next-generation monoclonal antibody biosimilar aimed at treating cancer and autoimmune diseases. As part of this collaboration, Ipca will transfer the late-stage development, clinical manufacturing, and commercial supply operations to BSS’s 200,000 square foot facility in Puerto Rico.
In other industry news, Lupin has received tentative approval from the U.S. Food and Drug Administration (FDA) for its generic version of the combination tablets of Bictegravir, Emtricitabine, and Tenofovir Alafenamide, which are used in the treatment of human immunodeficiency virus (HIV) infection.
Glenmark Specialty SA, a subsidiary of Glenmark Pharmaceuticals, has entered into an exclusive licensing and collaboration agreement with Hengrui Pharma to develop and commercialize Trastuzumab Rezetecan, a novel therapy for various cancer types. Under the terms of the agreement, Glenmark secures exclusive rights for the global development and commercialization of Trastuzumab Rezetecan, with the exception of Mainland China, Hong Kong SAR, Macao SAR, Taiwan Region, the United States, Canada, Europe, Japan, Russia, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, and Uzbekistan. Glenmark will pay an upfront fee of $18 million, with Hengrui eligible for regulatory and commercial milestone payments potentially reaching up to $1.093 billion.
Finally, Poly Medicure has entered into an agreement to acquire Medistream SA, including its subsidiaries Citieffe SRL in the United States and Mexico. The acquisition is valued at ₹324 crore.
The above reports highlight significant developments in the pharmaceutical sector with a focus on strategic partnerships and product approvals.
Published on September 25, 2025.
